Key Moments
- Pfizer increased its full-year revenue forecast to a range of $62 billion to $64.0 billion from a prior outlook of $60.5 billion to $62.5 billion.
- The company now projects adjusted earnings of $2.95 to $3.05 per share for the year, above its previous range of $2.80 to $3.00.
- Analysts’ consensus stood at $2.96 in annual per-share profit and $62.17 billion in 2026 revenue expectations.
Revised Guidance Driven by Eliquis Demand
Pfizer raised its full-year profit and sales projections on Tuesday, citing strong market demand for its blood thinner Eliquis.
The company now anticipates total revenue between $62 billion and $64.0 billion, an increase from its earlier guidance of $60.5 billion to $62.5 billion.
Updated Earnings Outlook
Alongside the higher sales forecast, Pfizer also lifted its adjusted earnings outlook. The U.S. drugmaker projects adjusted earnings of $2.95 to $3.05 per share for the year, compared with its prior estimate of $2.80 to $3.00 per share.
Comparison With Analyst Expectations
Analyst estimates show a more restrained view relative to the company’s new targets. On average, analysts were expecting annual per-share profit of $2.96 and 2026 revenue of $62.17 billion.
| Previous Pfizer Guidance | Updated Pfizer Guidance | Analyst Consensus | |
|---|---|---|---|
| Annual Revenue | $60.5 billion – $62.5 billion | $62 billion – $64.0 billion | $62.17 billion (2026) |
| Adjusted EPS | $2.80 – $3.00 | $2.95 – $3.05 | $2.96 |
The raised outlook underscores Pfizer’s reliance on Eliquis as a key revenue driver, with the company aligning its updated expectations against prevailing analyst forecasts.
TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover 
